| answer text |
<p>Hospital trusts submit data for secondary breast cancer diagnoses through the Cancer
Outcomes and Services Dataset (COSD) or Cancer Waiting Times (CWT) data collection
mechanisms. Data on the reported number of people diagnosed with secondary breast
cancers in 2014-2017 in England are available in the following table. Data for 2018
will be published in November 2020.</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Diagnoses
recorded in COSD</p></td><td><p>Diagnoses recorded in CWT</p></td></tr><tr><td><p>2017</p></td><td><p>4,754</p></td><td><p>6,739</p></td></tr><tr><td><p>2016</p></td><td><p>4,746</p></td><td><p>6,824</p></td></tr><tr><td><p>2015</p></td><td><p>4,218</p></td><td><p>6,808</p></td></tr><tr><td><p>2014</p></td><td><p>3,395</p></td><td><p>6,817</p></td></tr></tbody></table><p>Notes:</p><ol><li>Source:</li></ol><p><a
href="http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/recurrence"
target="_blank">http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/recurrence</a></p><ol
start="2"><li>Where a recurrence record has been reported by multiple trusts it will
be included once per trust. This means the totals will include some double-counting
of recurrences.</li><li>Counts from COSD and CWT cannot be combined as there will
duplication between the datasets.</li></ol><p> </p><p>The number of reported cases
is accepted as being significantly below the estimated number of secondary breast
cancers. The National Cancer Registration and Analysis Service is working closely
with cancer charities to improve data collection and submission by hospital trusts,
looking at how they can help improve completion rates and thus gain a better picture
of the burden of recurrence and metastatic disease across the health service.</p><p>Data
for secondary breast cancer diagnoses are not available at constituency level. Data
on how many people diagnosed with secondary breast cancer who were diagnosed less
than and more than five years after a diagnosis of primary breast cancer are not available.</p>
|
|
